Diagnostic Imaging's Weekly Scan: January 19 — January 25

The AI-powered AZchest CXR software reportedly offers 93.79 percent sensitivity and a 98.57 percent AUC for pneumothorax.

In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.

Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).

In the third episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss the challenges of expanded breast cancer screening amid a backdrop of radiologist shortages and ever-increasing volume on radiology worklists.

The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.

The cLung-RADS v2022 model offered a greater than 16 percent increase in the AUC in comparison to Lung-RADS 1.0 and Lung-RADS v2022 systems for predicting the invasiveness of pure ground-glass nodules.